前列腺癌改良病理淋巴结分期系统的开发与验证
基于国家癌症数据库118,450例根治性前列腺切除患者开发了按阳性淋巴结数目分层的新病理N分期,并在SEER数据库105,568例中验证。新分期将患者分为N0、N1、N2、N3a(3-5枚)和N3b(≥6枚),各组10年总死亡率分别为15%、35%、43%、52%和59%(p<0.05),区分度优于现行分期(c-index 0.669 vs 0.649)。
要点
- 阳性淋巴结数目是前列腺癌病理N分期的独立预后因素,风险随数目增加而升高。
- 新分期按0、1、2、3-5、≥6枚阳性淋巴结分为N0、N1、N2、N3a、N3b五组。
- 新分期对总死亡和前列腺癌特异性死亡的区分度优于现行单一N1分期。
核心结论
- 按阳性淋巴结数目分层可改善前列腺癌病理淋巴结分期的风险区分能力。
研究设计与样本
- 开发队列为118,450例在国家癌症数据库接受根治性前列腺切除的非转移性前列腺癌患者。
- 验证队列为105,568例在SEER数据库接受根治性前列腺切除的非转移性前列腺癌患者。
- 采用多变量Cox比例风险模型(限制性立方样条)评估阳性淋巴结数目与总死亡的非线性关联,并用递归分割分析推导新分期。
主要发现
- 多变量Cox分析中,总死亡风险随阳性淋巴结数目增加而升高至4枚(每增加1枚HR 1.30,95%CI 1.23-1.38),超过4枚后风险增加无统计学意义(HR 1.05,95%CI 0.99-1.11)。
- 开发队列递归分割分析确定最佳截点为0枚(N0,参照)、1枚(N1:HR 1.40,95%CI 1.25-1.58)、2枚(N2:HR 1.67,95%CI 1.40-1.99)、3-5枚(N3a:HR 2.18,95%CI 0.84-2.60)和≥6枚(N3b:HR 3.00,95%CI 2.37-3.79)。
- 验证队列中各组10年总死亡率分别为N0 15%、N1 35%、N2 43%、N3a 52%、N3b 59%(p<0.05),前列腺癌特异性死亡率亦呈相应差异。
- 新分期对淋巴结阳性患者生存分类的乐观校正c-index为0.669(95%CI 0.668-0.671),优于现行分期的0.649(95%CI 0.648-0.651)。
关键数值与推荐
- 新分期节点:N0为0枚阳性淋巴结;N1为1枚;N2为2枚;N3a为3-5枚;N3b为≥6枚。
- N3a组HR的95%CI下限为0.84,提示该组风险估计精度有限。
临床怎么用
- 病理报告应明确阳性淋巴结数目,以支持按新分期进行风险分层。
- 淋巴结阳性患者可根据阳性淋巴结数目(1、2、3-5、≥6枚)评估总死亡和前列腺癌特异性死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate cancer pathological nodal staging uses a single category for all node-positive patients. We sought to improve risk stratification by creating and validating a novel pathological nodal staging system incorporating number of metastatic lymph nodes (+LNs). MATERIALS AND METHODS: A total of 118,450 men who underwent radical prostatectomy for nonmetastatic prostate cancer in the National Cancer Database comprised our development cohort. Multivariable Cox proportional hazards analysis with restricted cubic splines was used to assess the nonlinear association between number of +LNs and overall mortality (OM). A novel staging system based on number of +LNs was derived by recursive partitioning analysis. The staging system was validated for prediction of OM and prostate-specific mortality in 105,568 men with nonmetastatic prostate cancer undergoing radical prostatectomy from the Surveillance, Epidemiology, and End Results database. Discrimination was assessed via Harrell's c-index. RESULTS: In multivariable Cox analysis, OM risk increased with higher number of +LNs up to 4 (HR 1.30 per each LN+, 95% CI 1.23-1.38), with a nonstatistically significant increase in risk (HR 1.05, 95% CI 0.99-1.11) beyond 4 +LN. In the development cohort, recursive partitioning analysis identified optimal cutoffs at 0 (N0: referent), 1 (N1: HR 1.40, 95% CI 1.25-1.58), 2 (N2: HR 1.67, 95% CI 1.40-1.99), 3-5 (N3a: HR 2.18, 95% CI 0.84-2.60) and ≥6 (N3b: HR 3.00, 95% CI 2.37-3.79) +LNs. In the validation cohort, these groups had markedly different 10-year OM (0+ LNs, N0: 15%; 1+ LN, N1: 35%; 2+ LNs, N2: 43%; 3-5 +LNs, N3a: 52%; and ≥6 +LNs, N3b: 59%; p <0.05) and prostate-specific mortality. The novel staging system improved survival classification over current staging for node-positive patients (optimism-corrected c-index 0.669 [95% CI 0.668-0.671] vs 0.649 [95% CI 0.648-0.651]). CONCLUSIONS: Pathological nodal staging in prostate cancer is improved with stratification by number of +LNs.
引用
- Daskivich TJ, Luu M, Freedland SJ, et al. Development and Validation of an Improved Pathological Nodal Staging System in Men with Prostate Cancer. J Urol. 2021. PMID: 34694160. doi:10.1097/JU.0000000000002256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。